PetLife Pharmaceuticals reports the First of Three Preclinical Studies in their pre-INAD Process for Vitalzul. Blue Scorpion Venom Toxicity Study Results Show No Adverse Reactions across Multiple Dosing Levels.
GlobeNewswire "Press Releases"
Hancock, MD , Jan. 10, 2017 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, received the initial Acute Toxicity study results, part of the pre-INAD and FDA /CVM submission protocol.
This is a first of its kind study, confirming PetLifes in-house research on Venenotherapy, with Blue Scorpion venom, having no toxic side effects.
As part of the pre-clinical study protocol, our Blue Scorpion venom formulation was evaluated in an Acute Toxicity study in mice (1). After administration for 14 days at 1X, 5X and 10X times dosing, the Blue Scorpion venom formulation was well tolerated and no adverse effects were observed at any of the dosing levels. All study animals gained weight as expected based on clinical observation and upon necropsy, there was no evidence to suggest any gross organ pathology.
Preparations for the Cell Line and Pharmacokinetic (PK) and Pharmacodynamic (PD) studies are now underway. These studies are required to meet and file the INAD application with the FDA /CVM. PetLife anticipates completing these studies and filing the application within the next 6 months.
We are excited to announce the stellar results of our first toxicity study with our partner InnoVision. This study sets the stage for the next steps in preparation for FDA /CVM submission of PetLifes Vitalzul, including upcoming Cell Line Studies and additional toxicity studies. Cell lines to be investigated include glioma, bladder and lung cancers, additionally, hematological malignancies will be studied stated Dr. Salvagno , CEO of PetLife Pharmaceuticals .
